Ovagen
EDL Tripeptide | Liver & GI Bioregulator
Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.
Mechanism of Action
Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.
Key Benefits
- Reduces long-term liver fibrosis
- Protects GI mucosal layer
- Defense against antibiotic damage
- Protection from environmental toxins
- May protect against chemotherapy GI effects
- Tissue-specific targeting via PEPT transporters
- Direct DNA regulation
- Part of comprehensive anti-aging protocols
EDLGlutamic Acid
Position 1
Aspartic Acid
Position 2
Leucine
Position 3
Liver Support
- Liver Fibrosis
Reduces long-term fibrosis development in liver tissue.
- Hepatoprotection
Protects liver through gene expression regulation.
GI Protection
- Mucosal Protection
Helps protect GI mucosal layer from various insults.
- Antibiotic Recovery
May protect GI tract from antibiotic-induced damage.
- Toxin Defense
Protects against environmental toxin effects on GI tract.
Anti-Aging
- Liver Aging
Addresses age-related liver changes through bioregulation.
- GI Aging
Supports GI tract function during aging.
Available in capsule form for oral administration. As a tripeptide, Ovagen is transported via PEPT1/PEPT2 transporters for targeted delivery to liver and GI tissue. Typical protocol involves 10-20 day cycles.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | Oral capsules |
| Maintenance | 10 mg | 2-3 cycles yearly | Oral capsules |
Complementary liver bioregulators with different sequences and mechanisms.
Both support liver health through different pathways.
Often combined in comprehensive anti-aging Khavinson protocols.
Both support GI health; different mechanisms.
Gene expression modulation begins
Effects persist due to epigenetic changes
Liver and GI function improvements
Cumulative benefits with periodic cycles
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Stop Signs - Discontinue if:
- Allergic reactions
- Unusual GI or liver symptoms
Contraindications
- Active liver emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
Good Signs
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Warning Signs
- Unknown source or purity
- Do not confuse with FSH derivative of same name
Bad Signs
- Discoloration
- Unusual odor
- Damaged packaging
- Khavinson Peptide Bioregulators OverviewAdvances in Gerontology (2020)
Ovagen (EDL) is a tripeptide bioregulator with effects on liver and GI tract.
- POT Family Transporters and Peptide BioregulatorsDrug Metabolism Reviews (2018)
Di- and tripeptides are transported via PEPT1/PEPT2, explaining tissue-specific targeting.
- Peptide Bioregulators and Liver FibrosisExperimental Gerontology (2019)
Short peptides reduce long-term fibrosis in liver tissue through gene expression regulation.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.